Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07189936 · ClinicalTrials.gov registry record · Phase 2
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
A Phase 2 study of SARS CoV 2 Infection and Post-Acute COVID-19 Syndrome, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07189936 is a Phase 2 study of SARS CoV 2 Infection and Post-Acute COVID-19 Syndrome that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 50 participants, below the 4,963-participant average among 28 other SARS CoV 2 Infection trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07189936, a Phase 2 study of SARS CoV 2 Infection and Post-Acute COVID-19 Syndrome, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Long COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection. Approximately 7% of individuals who recover from SARS-Cov-2 infection develop Long COVID. Long COVID Postural Orthostatic Tachycardia Syndrome (LCPOTS) symptoms include fatigue, exercise intolerance, orthostatic intolerance, syncope, and heightened orthostatic tachycardia. Research has found that decreased parasympathetic activity in LCPOTS increases the production of highly immunogenic neoantigens Isolevuglandins (IsoLG-adducts). IsoLG-adducts induce formation of circulating monocyte/T cell complexes(doublets) leading to the persistent and unresolved immune response that continues after the initial infection. The purpose of the this research, is to study the effects of 2-hydroxybenzylamine (2-HOBA), an Iso-LG-adduct scavenger, its effects in immune markers and compare it with Placebo
Conditions Studied
Interventions
- DRUG To Measure levels of circulating monocyte/ T cell doublets at Baseline
- DRUG To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment
- DRUG To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment
- DIAGNOSTIC_TEST To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA
- DIAGNOSTIC_TEST To Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo
Study Locations (1)
Tennessee
- Cyndya Shibao - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-12-18 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07189936
The ClinicalTrials.gov registry entry for NCT07189936 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,963-participant average among 28 other SARS CoV 2 Infection trials with a reported enrollment target (99% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with SARS CoV 2 Infection appearing as the primary indexed condition, and to 5 interventions - of which To Measure levels of circulating monocyte/ T cell doublets at Baseline is the first listed.
NCT07189936 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT07189936 about?
NCT07189936 is a clinical study titled "Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS". Long COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection. Approximately 7% of individuals who recover from SARS-Cov-2 infection develop Long COVID. Long COVID Postural Orthostatic Tachycardia Syndrome (LCP...
What is the current status of trial NCT07189936?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-12-18. Estimated completion is 2029-06-30.
What conditions does trial NCT07189936 study?
This clinical trial studies the following conditions: SARS CoV 2 Infection, Post-Acute COVID-19 Syndrome, Long Covid19, Postural Tachycardia Syndrome (POTS).
What interventions are being tested in trial NCT07189936?
The interventions under investigation include: To Measure levels of circulating monocyte/ T cell doublets at Baseline (DRUG), To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment (DRUG), To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment (DRUG), To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA (DIAGNOSTIC_TEST), To Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07189936?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07189936 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS CoV 2 Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
COMPLETED · Phase 2
-
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
COMPLETED · Phase 2
-
Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection
COMPLETED · Phase 2
-
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
COMPLETED · Phase 2
-
Exercise in Child Health
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.